查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1969262

成人疫苗市場：按疫苗類型、疫苗技術、給藥途徑、年齡層、通路和全球預測（2026-2032 年）分類

Adult Vaccines Market by Vaccine Type, Vaccine Technology, Route Of Administration, Age Group, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年成人疫苗市值為207.7億美元，預計2026年將成長至225.8億美元，複合年成長率為8.46%，預計到2032年將達到366.8億美元。

主要市場統計數據
基準年 2025 207.7億美元
預計年份：2026年 225.8億美元
預測年份 2032 366.8億美元
複合年成長率 (%) 8.46%

從策略觀點看成人免疫生態系統：重點關注關鍵促進因素、相關人員需求以及實證決策的基本背景。

成人免疫接種領域正經歷重大變革，這場變革受到科學突破、人口結構變化和公共衛生優先事項演變的共同影響。產業、醫療服務提供者和相關人員正努力應對技術創新、患者期望和報銷動態之間錯綜複雜的相互作用，這些因素共同決定了哪些預防策略能夠有效推廣。為了應對這項挑戰，決策者必須平衡短期營運壓力與對產品研發和生產韌性的長期投資。

對指導成人疫苗發展、供應和策略競爭重組的結構和技術轉折點進行分析考察。

近年來，變革性的變化加速發生，重新定義了成人疫苗的研發、生產、分發和銷售方式。核酸平台和重組技術的進步縮短了研發週期，並實現了更具針對性的免疫抗原性原性，提高了人們對疫苗研發速度和擴充性的期望。同時，數位健康和​​數據分析技術也使得針對成人族群的疫苗接種更加精準，並改善了上市後監測，從而加強了安全性監測和真實世界療效證據的取得。

對近期美國關稅政策對疫苗供應鏈、採購經濟和戰略製造選擇的累積影響全面評估。

近期關稅措施的累積影響波及整個疫苗供應鏈，波及原料採購、生產成本及分銷物流。關稅調整提高了配方、管瓶和低溫運輸耗材等某些投入品和組件的到岸成本，迫使製造商重新評估供應商合約和庫存管理政策。因此，各組織更重視近岸外包、長期供應商合約和經認證的多供應商策略，以減輕貿易摩擦的影響。

我們將對疫苗類型、平台技術、給藥途徑、分銷管道和成人年齡層進行綜合細分分析，以確定策略性機會叢集。

詳細的細分分析揭示了臨床需求、技術成熟度和分銷管道趨勢的交匯點，從而創造了差異化的機會。疫苗類型包括使用去活化疫苗、mRNA疫苗、蛋白質次單元疫苗和病毒載體方法製備的COVID-19疫苗；肝炎疫苗，分為聯合製劑、甲型肝炎疫苗和乙型肝炎疫苗；帶狀皰疹疫苗，分為欣格瑞（Shingrix）和佐斯塔瓦克斯（Zostavax）；HPV疫苗，分為9價、2000KKen氣和腦膜炎。更廣泛的類別包括麻疹、腮腺炎、德國麻疹（MMR）疫苗、大流行性流感疫苗、肺炎球菌疫苗（如PCV13/15/20和PPSV23）、季節性流感疫苗、百白破疫苗（包括Td變異株）和水痘製劑。這種多樣性表明，產品層面的差異化仍然是決定臨床定位和採購優先順序的關鍵因素。

從區域觀點來看，我們分析不同的醫療保健系統、管理體制和供給能力如何影響全球市場的疫苗引進和部署策略。

區域趨勢正以不同的方式影響需求模式、監管方式和供應鏈結構。在美洲，除了商業免疫計畫和私人採購管道外，大規模公共免疫計畫也在進行，導致自願性成人免疫宣傳活動和雇主主導的免疫計畫並存，形成了一種複雜的局面。在歐洲和中東及非洲，監管協調和多元化公共資金模式的努力正在影響疫苗採購計畫和新疫苗技術的應用，而低溫運輸基礎設施的差異則繼續推動優先投資。

對決定成人疫苗研發和供應領域領導地位的競爭定位、策略聯盟和營運能力進行全面的產業分析。

成人疫苗領域的競爭動態由成熟的跨國公司、新興生物技術專家和能夠快速擴大生產規模的契約製造組織 (CMO) 共同塑造。領先的製藥和生物技術公司正在推動平台多元化，致力於開發下一代疫苗結構並最佳化現有產品的生命週期管理。平台創新者與大型生產者之間的合作日益增多，將科學研究的彈性與生產的可靠性結合。這些合作正變得越來越具有戰略意義，其範圍已從簡單的授權授權擴展到共同開發、區域生產協議和風險共用機制。

為製造商、支付方和公共衛生領導者提供切實可行的策略建議，以增強韌性、加快部署並最佳化成人免疫接種效果。

產業界和政策制定者必須採取切實可行的多管齊下的策略，將科學潛力轉化為群體層面的保護。首先，應優先投資模組化製造和區域產能合作，以降低貿易夥伴關係波動風險，並在需求激增時快速產能擴張。其次，應整合技術藍圖，平衡短期供給需求與長期平台投資，確保從研發早期階段就使臨床策略與監理策略保持一致。第三，應透過創造強調真實世界療效、安全性和衛生經濟價值的證據，加強與商業部門和支付者的合作。

為了確保研究結果的可靠性，我們將對我們的研究設計進行透明的解釋，該設計融合了定性訪談、二手證據整合和交叉檢驗的分析框架。

支持這些發現的研究結合了定性專家訪談、有針對性的二手文獻整合以及結構化的檢驗練習。關鍵投入包括與臨床負責人、供應鏈經理、監管專家和支付方進行磋商，以了解實際營運中的限制和策略重點。二手分析整合了同行評審的科學文獻、監管指導文件和公共衛生政策聲明，以確保技術和監管方面的觀察結果是基於最新證據。

本文簡要概述了決定成人免疫計劃擴展及其永續性。

成人疫苗領域既充滿機會也面臨挑戰。儘管科技進步拓展了預防干涉措施的選擇範圍，但從創新到有效性的轉化需要生產、監管、支付方和交付系統等各環節的協調努力。在技​​術採納、通路最佳化以及區域生產結構韌性等方面的策略選擇，將決定哪些項目能夠實現永續規模化，哪些項目將面臨持續的挑戰。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：成人疫苗市場：依疫苗類型分類

  • 冠狀病毒感染疾病（COVID-19）
    • 失活
    • mRNA
    • 蛋白質次單元
    • 病毒載體
  • 肝炎
    • 聯合疫苗
    • 甲型肝炎
    • B型肝炎
  • 帶狀皰疹
    • 定序
    • 佐斯塔瓦茨
  • HPV
    • 九價
    • 二價
    • 四價
  • 腦膜炎奈瑟菌
    • MenACWY
    • B族腦膜炎雙球菌
  • MMR
  • 大流行性流感
  • 肺炎球菌
    • PCV13
    • PCV15
    • PCV20
    • PPSV23
  • 季節性流感
  • Tdap
    • Td
    • Tdap
  • 水痘

第9章：成人疫苗市場：依疫苗技術分類

  • 組合型
  • DNA
    • 遺傳編碼
    • 質體DNA
  • 失活
  • 活病毒疫苗
  • mRNA
    • 核苷修飾型
    • 自放大
  • 重組
  • 類毒素
    • 白喉類毒素
    • 破傷風類毒素
  • 病毒載體
    • 非複製型
    • 複製類型

第10章 成人疫苗市場：依給藥途徑分類

  • 皮內給藥
  • 肌肉內部
  • 鼻腔
  • 口服
  • 皮下注射

第11章 成人疫苗市場：依年齡層別分類

  • 18-30歲
  • 31至45歲
  • 46至60歲
  • 61歲或以上

第12章 成人疫苗市場：依通路分類

  • 診所
  • 醫院
  • 網路藥房
  • 公共衛生中心
  • 零售藥房

第13章 成人疫苗市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 成人疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 成人疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國：成人疫苗市場

第17章 中國：成人疫苗市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Bavarian Nordic A/S
  • CSL Limited
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novavax, Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Ltd.
  • Valneva SE
Product Code: MRR-535C6291878F

The Adult Vaccines Market was valued at USD 20.77 billion in 2025 and is projected to grow to USD 22.58 billion in 2026, with a CAGR of 8.46%, reaching USD 36.68 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 20.77 billion
Estimated Year [2026] USD 22.58 billion
Forecast Year [2032] USD 36.68 billion
CAGR (%) 8.46%

A strategic orientation to the adult immunization ecosystem highlighting key drivers, stakeholder imperatives, and the essential context for evidence-based decision-making

The adult immunization environment is at a pivotal moment, shaped by scientific breakthroughs, demographic shifts, and evolving public health priorities. Stakeholders across industry, healthcare delivery, and policy are navigating a complex interplay of technological innovation, patient expectations, and reimbursement dynamics that together determine which prevention strategies will scale effectively. In response, decision-makers must reconcile near-term operational pressures with longer-term investments in product development and manufacturing resilience.

This executive summary synthesizes core trends and practical implications for leaders focused on adult vaccines. It frames the competitive landscape through the lens of vaccine technology diversity, route of administration preferences, distribution channel evolution, and age-segmented demand patterns. In doing so, it clarifies the strategic choices that will govern portfolio prioritization, partnerships, and supply continuity over the coming strategic planning cycles. Ultimately, this introduction sets the context for subsequent sections that unpack transformative shifts, regulatory and trade impacts, segmentation-driven opportunity, and region-specific dynamics.

An analytical exploration of the structural and technological inflection points reshaping adult vaccine development, delivery, and strategic competitive positioning

Recent years have catalyzed transformative shifts that are redefining how adult vaccines are developed, manufactured, distributed, and adopted. Advances in nucleic acid platforms and recombinant technologies have shortened development timelines and enabled more targeted immunogenic profiles, which in turn has raised expectations for speed and scalability. Parallel to these scientific advances, digital health and data analytics are enabling more precise targeting of adult cohorts and improved post-market surveillance, strengthening safety monitoring and real-world effectiveness evidence.

Concurrently, supply chain resilience has assumed strategic importance, prompting firms to reassess sourcing strategies, diversify manufacturing footprints, and pursue flexible fill-finish capacity. Regulatory pathways have evolved to balance expedited access with rigorous safety standards, increasing the importance of proactive regulatory engagement and robust clinical evidence planning. Taken together, these shifts are creating new competitive arenas where agility in technology adoption and partnership orchestration will determine which players capture sustained value.

A comprehensive assessment of how recent United States tariff policies have cumulatively affected vaccine supply chains, procurement economics, and strategic manufacturing choices

The cumulative impact of recent tariff actions has reverberated through vaccine supply chains, affecting raw material sourcing, manufacturing economics, and distribution logistics. Tariff adjustments have increased landed costs for certain inputs and components used in formulation, vials, and cold chain consumables, prompting manufacturers to reassess supplier agreements and inventory policies. As a result, organizations are placing greater emphasis on nearshoring, long-term supplier contracts, and qualified multiple-supplier strategies to mitigate exposure to trade frictions.

Moreover, the tariff environment has influenced capital allocation decisions for production capacity expansion and strategic stockholding. In response, some stakeholders have accelerated investments in domestic fill-and-finish capacity and technology transfer programs while others have renegotiated commercial terms to preserve margins. Regulatory coordination and diplomatic channels have become more salient in advanced planning, since tariff-induced cost pressures can translate into procurement tender dynamics and reimbursement negotiations. Looking ahead, adaptive sourcing, diversified logistics arrangements, and proactive regulatory engagement are core mitigation levers that can preserve continuity of supply and protect affordability for adult immunization programs.

An integrated segmentation analysis that aligns vaccine types, platform technologies, administration routes, distribution channels, and adult age cohorts to reveal strategic opportunity clusters

A granular view of segmentation reveals where clinical need, technology readiness, and delivery channel dynamics converge to create differentiated opportunities. By vaccine type, the landscape spans Covid 19 vaccines analyzed across inactivated, mRNA, protein subunit, and viral vector approaches; hepatitis vaccines parsed into combined formulations, hepatitis A, and hepatitis B; herpes zoster vaccines differentiated by Shingrix and Zostavax; HPV products categorized as 9-valent, bivalent, and quadrivalent; meningococcal vaccines distinguished between MenACWY and MenB; and a broader set including MMR, pandemic influenza, pneumococcal options such as PCV13, PCV15, PCV20, and PPSV23, seasonal influenza, Tdap with Td variants, and varicella formulations. This spectrum indicates that product-level differentiation remains a primary determinant of clinical positioning and procurement preference.

Based on vaccine technology, the field encompasses conjugate approaches, DNA platforms split into gene-encoded and plasmid DNA, inactivated formulations, live attenuated options, mRNA platforms including nucleoside-modified and self-amplifying variants, recombinant subunit technologies, toxoid categories such as diphtheria and tetanus toxoids, and viral vector systems that are either non-replicating or replicating. Route of administration also matters, with intradermal, intramuscular, intranasal, oral, and subcutaneous delivery routes affecting patient acceptance, administration costs, and cold chain considerations. Distribution channels range from clinics, hospitals, and public health centers to retail pharmacies and online pharmacies, each with distinct procurement cycles, refrigeration infrastructures, and patient touchpoints. Finally, age segmentation among adults-18 to 30, 31 to 45, 46 to 60, and 61 and above-drives clinical priorities, uptake incentives, and communication strategies. When layered together, these segmentation axes enable nuanced targeting of clinical value propositions, pricing models, and rollout sequencing.

A regional perspective that deciphers how distinct healthcare systems, regulatory regimes, and supply capabilities shape vaccine adoption and deployment strategies across global markets

Regional dynamics are shaping demand patterns, regulatory approaches, and supply chain architectures in distinct ways. In the Americas, commercial vaccination programs and private-sector procurement channels are complemented by large public immunization initiatives, producing a mixed landscape where voluntary adult vaccination campaigns coexist with employer-sponsored programs. Across Europe, Middle East & Africa, regulatory harmonization efforts and varying public financing models influence procurement timelines and the adoption of newer vaccine technologies, while disparities in cold chain infrastructure continue to drive priority investments.

In Asia-Pacific, rapid manufacturing scale-up, strong domestic industry participation, and targeted government immunization campaigns have accelerated adoption curves for a range of adult vaccines. These regional patterns underscore the importance of aligning portfolio strategies with local regulatory pathways, payment mechanisms, and distribution networks. Strategic partnerships, regional manufacturing collaborations, and context-sensitive communication campaigns can bridge gaps between global product development and local delivery capabilities, thereby improving access and program sustainability.

An industry-focused synthesis of competitive positioning, strategic alliances, and the operational capabilities that determine leadership in adult vaccine development and supply

Competitive dynamics in the adult vaccine arena are driven by a mix of established multinationals, emerging biotech specialists, and contract manufacturing organizations that enable rapid scale. Leading pharmaceutical and biotech companies are advancing platform diversification, pursuing both next-generation vaccine constructs and lifecycle management of legacy products. Partnerships between platform innovators and large-scale manufacturers have proliferated, combining scientific agility with production reliability. These collaborations are increasingly strategic, extending beyond licensing to encompass co-development, regional manufacturing agreements, and shared risk frameworks.

Concurrently, contract development and manufacturing organizations have become critical enablers, offering flexible capacity, fill-finish services, and regulatory support for technology transfers. Competitive advantage is increasingly determined by integrated capabilities across R&D, regulatory affairs, and global distribution networks, along with the ability to demonstrate real-world effectiveness and cost-effectiveness to payers. Companies that can align clinical differentiation with operational resilience and payer-aligned pricing strategies are best positioned to sustain growth in adult vaccination programs.

Actionable strategic recommendations for manufacturers, payers, and public health leaders to strengthen resilience, accelerate adoption, and optimize adult immunization outcomes

Leaders in industry and policy must adopt pragmatic, multi-dimensional strategies to translate scientific promise into population-level protection. First, prioritize modular manufacturing investments and regional capacity partnerships to reduce exposure to trade policy volatility and to enable rapid scale-up when demand surges. Second, integrate technology roadmaps that balance near-term delivery requirements with longer-term platform investments, ensuring that clinical and regulatory strategies align from the earliest development stages. Third, strengthen commercial and payer engagement through evidence generation that emphasizes real-world effectiveness, safety, and health economic value.

In addition, refine distribution partnerships by aligning cold chain capabilities with channel-specific needs and by exploring hybrid models that leverage clinical sites, retail pharmacies, and validated online channels to maximize reach. Enhance patient-centered communication strategies that are tailored by age cohort and risk profile, and embed digital tools to facilitate scheduling, reminders, and adverse event reporting. Finally, institutionalize scenario planning that incorporates trade policy shifts, supply disruptions, and regulatory acceleration, so that contingency actions can be executed with minimal disruption to program continuity.

A transparent explanation of the research design that integrates qualitative interviews, secondary evidence synthesis, and cross-validated analytical frameworks to ensure credible insights

The research underpinning these insights combined qualitative expert interviews, targeted secondary literature synthesis, and structured validation exercises. Primary inputs included consultations with clinical leaders, supply chain managers, regulatory specialists, and payers to capture real-world operational constraints and strategic priorities. Secondary analysis synthesized peer-reviewed science, regulatory guidance documents, and public health policy statements to ensure that technological and regulatory observations were grounded in current evidence.

Findings were triangulated through cross-validation with commercial leaders and program implementers to stress-test assumptions and identify practical mitigation options. Segmentation frameworks were mapped by aligning vaccine types, technology platforms, administration routes, distribution channels, and adult age cohorts to observed deployment patterns. Throughout the methodology, emphasis was placed on transparency of assumptions, reproducibility of analytical steps, and clear delineation between evidence-based conclusions and scenario-based implications.

A concise synthesis of the strategic imperatives and operational levers that will determine success in expanding adult immunization coverage and program sustainability

The adult vaccines landscape is defined by simultaneous opportunity and complexity: scientific advances have expanded the feasible portfolio of preventative interventions, but the translation from innovation to impact requires coordinated action across manufacturing, regulatory, payer, and delivery systems. Strategic choices around technology adoption, distribution channel optimization, and regional manufacturing resilience will determine which programs achieve sustainable scale and which face persistent barriers.

To navigate this environment, stakeholders must prioritize adaptable supply strategies, evidence-driven payer engagement, and targeted communication to adult cohorts. When executed coherently, these elements can accelerate uptake, preserve affordability, and strengthen public health preparedness. The insights in this summary are designed to assist leaders in aligning near-term operational decisions with long-term value creation for adult immunization programs.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Adult Vaccines Market, by Vaccine Type

  • 8.1. Covid 19
    • 8.1.1. Inactivated
    • 8.1.2. Mrna
    • 8.1.3. Protein Subunit
    • 8.1.4. Viral Vector
  • 8.2. Hepatitis
    • 8.2.1. Combined
    • 8.2.2. Hepatitis A
    • 8.2.3. Hepatitis B
  • 8.3. Herpes Zoster
    • 8.3.1. Shingrix
    • 8.3.2. Zostavax
  • 8.4. Hpv
    • 8.4.1. 9-Valent
    • 8.4.2. Bivalent
    • 8.4.3. Quadrivalent
  • 8.5. Meningococcal
    • 8.5.1. MenACWY
    • 8.5.2. MenB
  • 8.6. Mmr
  • 8.7. Pandemic Influenza
  • 8.8. Pneumococcal
    • 8.8.1. Pcv13
    • 8.8.2. Pcv15
    • 8.8.3. Pcv20
    • 8.8.4. Ppsv23
  • 8.9. Seasonal Influenza
  • 8.10. Tdap
    • 8.10.1. Td
    • 8.10.2. Tdap
  • 8.11. Varicella

9. Adult Vaccines Market, by Vaccine Technology

  • 9.1. Conjugate
  • 9.2. Dna
    • 9.2.1. Gene Encoded
    • 9.2.2. Plasmid Dna
  • 9.3. Inactivated
  • 9.4. Live Attenuated
  • 9.5. Mrna
    • 9.5.1. Nucleoside Modified
    • 9.5.2. Self Amplifying
  • 9.6. Recombinant
  • 9.7. Toxoid
    • 9.7.1. Diphtheria Toxoid
    • 9.7.2. Tetanus Toxoid
  • 9.8. Viral Vector
    • 9.8.1. Non Replicating
    • 9.8.2. Replicating

10. Adult Vaccines Market, by Route Of Administration

  • 10.1. Intradermal
  • 10.2. Intramuscular
  • 10.3. Intranasal
  • 10.4. Oral
  • 10.5. Subcutaneous

11. Adult Vaccines Market, by Age Group

  • 11.1. 18 To 30
  • 11.2. 31 To 45
  • 11.3. 46 To 60
  • 11.4. 61 And Above

12. Adult Vaccines Market, by Distribution Channel

  • 12.1. Clinics
  • 12.2. Hospitals
  • 12.3. Online Pharmacies
  • 12.4. Public Health Centers
  • 12.5. Retail Pharmacies

13. Adult Vaccines Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Adult Vaccines Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Adult Vaccines Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Adult Vaccines Market

17. China Adult Vaccines Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Bavarian Nordic A/S
  • 18.6. CSL Limited
  • 18.7. GlaxoSmithKline plc
  • 18.8. Johnson & Johnson
  • 18.9. Merck & Co., Inc.
  • 18.10. Moderna, Inc.
  • 18.11. Novavax, Inc.
  • 18.12. Novavax, Inc.
  • 18.13. Pfizer Inc.
  • 18.14. Sanofi S.A.
  • 18.15. Takeda Pharmaceutical Company Ltd.
  • 18.16. Valneva SE

LIST OF FIGURES

  • FIGURE 1. GLOBAL ADULT VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ADULT VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ADULT VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ADULT VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ADULT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ADULT VACCINES MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ADULT VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ADULT VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ADULT VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ADULT VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ADULT VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ADULT VACCINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ADULT VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ADULT VACCINES MARKET SIZE, BY COVID 19, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ADULT VACCINES MARKET SIZE, BY COVID 19, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ADULT VACCINES MARKET SIZE, BY COVID 19, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ADULT VACCINES MARKET SIZE, BY COVID 19, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ADULT VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ADULT VACCINES MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ADULT VACCINES MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ADULT VACCINES MARKET SIZE, BY MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ADULT VACCINES MARKET SIZE, BY MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ADULT VACCINES MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ADULT VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ADULT VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ADULT VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ADULT VACCINES MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ADULT VACCINES MARKET SIZE, BY HEPATITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ADULT VACCINES MARKET SIZE, BY HEPATITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ADULT VACCINES MARKET SIZE, BY HEPATITIS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ADULT VACCINES MARKET SIZE, BY COMBINED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ADULT VACCINES MARKET SIZE, BY COMBINED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ADULT VACCINES MARKET SIZE, BY COMBINED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ADULT VACCINES MARKET SIZE, BY HEPATITIS A, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ADULT VACCINES MARKET SIZE, BY HEPATITIS A, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ADULT VACCINES MARKET SIZE, BY HEPATITIS A, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ADULT VACCINES MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ADULT VACCINES MARKET SIZE, BY HEPATITIS B, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ADULT VACCINES MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ADULT VACCINES MARKET SIZE, BY SHINGRIX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ADULT VACCINES MARKET SIZE, BY SHINGRIX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ADULT VACCINES MARKET SIZE, BY SHINGRIX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ADULT VACCINES MARKET SIZE, BY ZOSTAVAX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ADULT VACCINES MARKET SIZE, BY ZOSTAVAX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ADULT VACCINES MARKET SIZE, BY ZOSTAVAX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ADULT VACCINES MARKET SIZE, BY HPV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ADULT VACCINES MARKET SIZE, BY HPV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ADULT VACCINES MARKET SIZE, BY HPV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ADULT VACCINES MARKET SIZE, BY HPV, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ADULT VACCINES MARKET SIZE, BY 9-VALENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ADULT VACCINES MARKET SIZE, BY 9-VALENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ADULT VACCINES MARKET SIZE, BY 9-VALENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ADULT VACCINES MARKET SIZE, BY BIVALENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ADULT VACCINES MARKET SIZE, BY BIVALENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ADULT VACCINES MARKET SIZE, BY BIVALENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ADULT VACCINES MARKET SIZE, BY QUADRIVALENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ADULT VACCINES MARKET SIZE, BY QUADRIVALENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ADULT VACCINES MARKET SIZE, BY QUADRIVALENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ADULT VACCINES MARKET SIZE, BY MENACWY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ADULT VACCINES MARKET SIZE, BY MENACWY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ADULT VACCINES MARKET SIZE, BY MENACWY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ADULT VACCINES MARKET SIZE, BY MENB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ADULT VACCINES MARKET SIZE, BY MENB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ADULT VACCINES MARKET SIZE, BY MENB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ADULT VACCINES MARKET SIZE, BY MMR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ADULT VACCINES MARKET SIZE, BY MMR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ADULT VACCINES MARKET SIZE, BY MMR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ADULT VACCINES MARKET SIZE, BY PANDEMIC INFLUENZA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ADULT VACCINES MARKET SIZE, BY PANDEMIC INFLUENZA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ADULT VACCINES MARKET SIZE, BY PANDEMIC INFLUENZA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ADULT VACCINES MARKET SIZE, BY PCV13, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ADULT VACCINES MARKET SIZE, BY PCV13, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ADULT VACCINES MARKET SIZE, BY PCV13, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ADULT VACCINES MARKET SIZE, BY PCV15, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ADULT VACCINES MARKET SIZE, BY PCV15, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ADULT VACCINES MARKET SIZE, BY PCV15, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ADULT VACCINES MARKET SIZE, BY PCV20, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ADULT VACCINES MARKET SIZE, BY PCV20, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ADULT VACCINES MARKET SIZE, BY PCV20, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ADULT VACCINES MARKET SIZE, BY PPSV23, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ADULT VACCINES MARKET SIZE, BY PPSV23, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ADULT VACCINES MARKET SIZE, BY PPSV23, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ADULT VACCINES MARKET SIZE, BY SEASONAL INFLUENZA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ADULT VACCINES MARKET SIZE, BY SEASONAL INFLUENZA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ADULT VACCINES MARKET SIZE, BY SEASONAL INFLUENZA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ADULT VACCINES MARKET SIZE, BY TDAP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ADULT VACCINES MARKET SIZE, BY TDAP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ADULT VACCINES MARKET SIZE, BY TDAP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ADULT VACCINES MARKET SIZE, BY TDAP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ADULT VACCINES MARKET SIZE, BY TD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ADULT VACCINES MARKET SIZE, BY TD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ADULT VACCINES MARKET SIZE, BY TD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ADULT VACCINES MARKET SIZE, BY TDAP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ADULT VACCINES MARKET SIZE, BY TDAP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ADULT VACCINES MARKET SIZE, BY TDAP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ADULT VACCINES MARKET SIZE, BY VARICELLA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ADULT VACCINES MARKET SIZE, BY VARICELLA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ADULT VACCINES MARKET SIZE, BY VARICELLA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ADULT VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ADULT VACCINES MARKET SIZE, BY CONJUGATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ADULT VACCINES MARKET SIZE, BY CONJUGATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ADULT VACCINES MARKET SIZE, BY CONJUGATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ADULT VACCINES MARKET SIZE, BY DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ADULT VACCINES MARKET SIZE, BY DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ADULT VACCINES MARKET SIZE, BY DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ADULT VACCINES MARKET SIZE, BY DNA, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ADULT VACCINES MARKET SIZE, BY GENE ENCODED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ADULT VACCINES MARKET SIZE, BY GENE ENCODED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ADULT VACCINES MARKET SIZE, BY GENE ENCODED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ADULT VACCINES MARKET SIZE, BY PLASMID DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ADULT VACCINES MARKET SIZE, BY PLASMID DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ADULT VACCINES MARKET SIZE, BY PLASMID DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ADULT VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ADULT VACCINES MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ADULT VACCINES MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ADULT VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ADULT VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ADULT VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ADULT VACCINES MARKET SIZE, BY MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ADULT VACCINES MARKET SIZE, BY MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ADULT VACCINES MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ADULT VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ADULT VACCINES MARKET SIZE, BY NUCLEOSIDE MODIFIED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ADULT VACCINES MARKET SIZE, BY NUCLEOSIDE MODIFIED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ADULT VACCINES MARKET SIZE, BY NUCLEOSIDE MODIFIED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ADULT VACCINES MARKET SIZE, BY SELF AMPLIFYING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ADULT VACCINES MARKET SIZE, BY SELF AMPLIFYING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ADULT VACCINES MARKET SIZE, BY SELF AMPLIFYING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ADULT VACCINES MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ADULT VACCINES MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ADULT VACCINES MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ADULT VACCINES MARKET SIZE, BY TOXOID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ADULT VACCINES MARKET SIZE, BY TOXOID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ADULT VACCINES MARKET SIZE, BY TOXOID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL ADULT VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ADULT VACCINES MARKET SIZE, BY DIPHTHERIA TOXOID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ADULT VACCINES MARKET SIZE, BY DIPHTHERIA TOXOID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL ADULT VACCINES MARKET SIZE, BY DIPHTHERIA TOXOID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ADULT VACCINES MARKET SIZE, BY TETANUS TOXOID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL ADULT VACCINES MARKET SIZE, BY TETANUS TOXOID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL ADULT VACCINES MARKET SIZE, BY TETANUS TOXOID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ADULT VACCINES MARKET SIZE, BY NON REPLICATING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL ADULT VACCINES MARKET SIZE, BY NON REPLICATING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ADULT VACCINES MARKET SIZE, BY NON REPLICATING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL ADULT VACCINES MARKET SIZE, BY REPLICATING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL ADULT VACCINES MARKET SIZE, BY REPLICATING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ADULT VACCINES MARKET SIZE, BY REPLICATING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ADULT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL ADULT VACCINES MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL ADULT VACCINES MARKET SIZE, BY INTRADERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL ADULT VACCINES MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL ADULT VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL ADULT VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL ADULT VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL ADULT VACCINES MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL ADULT VACCINES MARKET SIZE, BY INTRANASAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL ADULT VACCINES MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL ADULT VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL ADULT VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL ADULT VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL ADULT VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL ADULT VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL ADULT VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL ADULT VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL ADULT VACCINES MARKET SIZE, BY 18 TO 30, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL ADULT VACCINES MARKET SIZE, BY 18 TO 30, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL ADULT VACCINES MARKET SIZE, BY 18 TO 30, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL ADULT VACCINES MARKET SIZE, BY 31 TO 45, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL ADULT VACCINES MARKET SIZE, BY 31 TO 45, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL ADULT VACCINES MARKET SIZE, BY 31 TO 45, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL ADULT VACCINES MARKET SIZE, BY 46 TO 60, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL ADULT VACCINES MARKET SIZE, BY 46 TO 60, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL ADULT VACCINES MARKET SIZE, BY 46 TO 60, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL ADULT VACCINES MARKET SIZE, BY 61 AND ABOVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL ADULT VACCINES MARKET SIZE, BY 61 AND ABOVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL ADULT VACCINES MARKET SIZE, BY 61 AND ABOVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL ADULT VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL ADULT VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL ADULT VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL ADULT VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL ADULT VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL ADULT VACCINES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL ADULT VACCINES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL ADULT VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL ADULT VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL ADULT VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL ADULT VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL ADULT VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL ADULT VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL ADULT VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL ADULT VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL ADULT VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL ADULT VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 202. AMERICAS ADULT VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 203. AMERICAS ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. AMERICAS ADULT VACCINES MARKET SIZE, BY COVID 19, 2018-2032 (USD MILLION)
  • TABLE 205. AMERICAS ADULT VACCINES MARKET SIZE, BY HEPATITIS, 2018-2032 (USD MILLION)
  • TABLE 206. AMERICAS ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, 2018-2032 (USD MILLION)
  • TABLE 207. AMERICAS ADULT VACCINES MARKET SIZE, BY HPV, 2018-2032 (USD MILLION)
  • TABLE 208. AMERICAS ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 209. AMERICAS ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 210. AMERICAS ADULT VACCINES MARKET SIZE, BY TDAP, 2018-2032 (USD MILLION)
  • TABLE 211. AMERICAS ADULT VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. AMERICAS ADULT VACCINES MARKET SIZE, BY DNA, 2018-2032 (USD MILLION)
  • TABLE 213. AMERICAS ADULT VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 214. AMERICAS ADULT VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 215. AMERICAS ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 216. AMERICAS ADULT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. AMERICAS ADULT VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 218. AMERICAS ADULT VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA ADULT VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. NORTH AMERICA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA ADULT VACCINES MARKET SIZE, BY COVID 19, 2018-2032 (USD MILLION)
  • TABLE 222. NORTH AMERICA ADULT VACCINES MARKET SIZE, BY HEPATITIS, 2018-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, 2018-2032 (USD MILLION)
  • TABLE 224. NORTH AMERICA ADULT VACCINES MARKET SIZE, BY HPV, 2018-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 226. NORTH AMERICA ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA ADULT VACCINES MARKET SIZE, BY TDAP, 2018-2032 (USD MILLION)
  • TABLE 228. NORTH AMERICA ADULT VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA ADULT VACCINES MARKET SIZE, BY DNA, 2018-2032 (USD MILLION)
  • TABLE 230. NORTH AMERICA ADULT VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA ADULT VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 232. NORTH AMERICA ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA ADULT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 234. NORTH AMERICA ADULT VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA ADULT VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. LATIN AMERICA ADULT VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. LATIN AMERICA ADULT VACCINES MARKET SIZE, BY COVID 19, 2018-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA ADULT VACCINES MARKET SIZE, BY HEPATITIS, 2018-2032 (USD MILLION)
  • TABLE 240. LATIN AMERICA ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, 2018-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA ADULT VACCINES MARKET SIZE, BY HPV, 2018-2032 (USD MILLION)
  • TABLE 242. LATIN AMERICA ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 244. LATIN AMERICA ADULT VACCINES MARKET SIZE, BY TDAP, 2018-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA ADULT VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. LATIN AMERICA ADULT VACCINES MARKET SIZE, BY DNA, 2018-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA ADULT VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 248. LATIN AMERICA ADULT VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 250. LATIN AMERICA ADULT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA ADULT VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 252. LATIN AMERICA ADULT VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY COVID 19, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY HEPATITIS, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY HPV, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY TDAP, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY DNA, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPE ADULT VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPE ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPE ADULT VACCINES MARKET SIZE, BY COVID 19, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPE ADULT VACCINES MARKET SIZE, BY HEPATITIS, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPE ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPE ADULT VACCINES MARKET SIZE, BY HPV, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPE ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPE ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPE ADULT VACCINES MARKET SIZE, BY TDAP, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPE ADULT VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPE ADULT VACCINES MARKET SIZE, BY DNA, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPE ADULT VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPE ADULT VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPE ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPE ADULT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPE ADULT VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPE ADULT VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST ADULT VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 288. MIDDLE EAST ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST ADULT VACCINES MARKET SIZE, BY COVID 19, 2018-2032 (USD MILLION)
  • TABLE 290. MIDDLE EAST ADULT VACCINES MARKET SIZE, BY HEPATITIS, 2018-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, 2018-2032 (USD MILLION)
  • TABLE 292. MIDDLE EAST ADULT VACCINES MARKET SIZE, BY HPV, 2018-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 294. MIDDLE EAST ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST ADULT VACCINES MARKET SIZE, BY TDAP, 2018-2032 (USD MILLION)
  • TABLE 296. MIDDLE EAST ADULT VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST ADULT VACCINES MARKET SIZE, BY DNA, 2018-2032 (USD MILLION)
  • TABLE 298. MIDDLE EAST ADULT VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST ADULT VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 300. MIDDLE EAST ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST ADULT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 302. MIDDLE EAST ADULT VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST ADULT VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 304. AFRICA ADULT VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 305. AFRICA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. AFRICA ADULT VACCINES MARKET SIZE, BY COVID 19, 2018-2032 (USD MILLION)
  • TABLE 307. AFRICA ADULT VACCINES MARKET SIZE, BY HEPATITIS, 2018-2032 (USD MILLION)
  • TABLE 308. AFRICA ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, 2018-2032 (USD MILLION)
  • TABLE 309. AFRICA ADULT VACCINES MARKET SIZE, BY HPV, 2018-2032 (USD MILLION)
  • TABLE 310. AFRICA ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 311. AFRICA ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 312. AFRICA ADULT VACCINES MARKET SIZE, BY TDAP, 2018-2032 (USD MILLION)
  • TABLE 313. AFRICA ADULT VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 314. AFRICA ADULT VACCINES MARKET SIZE, BY DNA, 2018-2032 (USD MILLION)
  • TABLE 315. AFRICA ADULT VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 316. AFRICA ADULT VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 317. AFRICA ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 318. AFRICA ADULT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 319. AFRICA ADULT VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 320. AFRICA ADULT VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 321. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 322. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 323. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY COVID 19, 2018-2032 (USD MILLION)
  • TABLE 324. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY HEPATITIS, 2018-2032 (USD MILLION)
  • TABLE 325. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, 2018-2032 (USD MILLION)
  • TABLE 326. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY HPV, 2018-2032 (USD MILLION)
  • TABLE 327. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 328. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 329. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY TDAP, 2018-2032 (USD MILLION)
  • TABLE 330. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 331. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY DNA, 2018-2032 (USD MILLION)
  • TABLE 332. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 333. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 334. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 335. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 336. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 337. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 338. GLOBAL ADULT VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 339. ASEAN ADULT VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 340. ASEAN ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 341. ASEAN ADULT VACCINES MARKET SIZE, BY COVID 19, 2018-2032 (USD MILLION)
  • TABLE 342. ASEAN ADULT VACCINES MARKET SIZE, BY HEPATITIS, 2018-2032 (USD MILLION)
  • TABLE 343. ASEAN ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, 2018-2032 (USD MILLION)
  • TABLE 344. ASEAN ADULT VACCINES MARKET SIZE, BY HPV, 2018-2032 (USD MILLION)
  • TABLE 345. ASEAN ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 346. ASEAN ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 347. ASEAN ADULT VACCINES MARKET SIZE, BY TDAP, 2018-2032 (USD MILLION)
  • TABLE 348. ASEAN ADULT VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 349. ASEAN ADULT VACCINES MARKET SIZE, BY DNA, 2018-2032 (USD MILLION)
  • TABLE 350. ASEAN ADULT VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 351. ASEAN ADULT VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 352. ASEAN ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 353. ASEAN ADULT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 354. ASEA